ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 709,75
0,98%
Dow Jones
43 487,83
0,78%
DAX
20 903,39
1,31%
Brent Oil
80,005
0,00%
Bitcoin
102 917,46
-1,16%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Veru Inc (VERU) Cours

Veru Inc

Veru Inc (VERU)

NASDAQ
0,9754
0,1317
(15,61%)
Fermé 18 Janvier 10:00PM
Retardé de 15 minutes
0,98
0,0046
(0,47%)
Après les heures de négociation: 1:59AM
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
0,98
Prix Achat
0,9754
Prix Vente
0,9895
Volume échangé
4 914 874
0,826 Fourchette du Jour 0,9926
0,36 Plage de 52 semaines 1,92
Cap du marché
143,456M
Clôture Veille
0,8437
Ouverture
0,84
Dernière Transaction
1
@
0.97
Dernière heure de transaction
Volume financier
US$ 4 528 524
VWAP
0,921392
Volume moyen (3 m)
1 324 012
Actions en circulation
146 383 920
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-3,80
Bénéfice par action (BPA)
-0,26
Chiffre d'affairess
16,89M
Bénéfice net
-37,8M

À propos de Veru Inc

Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility, and novel chemotherapies for a variety of cancers. The company currently operates in two reporti... Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility, and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Sexual health business and Research & development. Some of its products include Zuclomiphene, Veru-111, Veru-100, FC2, and Roman Swipes. The company generates the majority of its revenue from the United States. Show more

Secteur
Pharmaceutical Preparations
Industrie
Fabricated Rubber Pds, Nec
Siège social
Madison, Wisconsin, USA
Fondé
2018
Veru Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker VERU. Le dernier cours de clôture d'Veru était de US$0,84. Au cours de la dernière année, les actions de Veru ont été négociées dans une fourchette de prix de US$ 0,36 à US$ 1,92.

Veru compte actuellement 146 383 920 actions en circulation. La capitalisation boursière d'Veru est de US$123,50 million. Veru a un ratio cours/bénéfice (ratio PE) de -3.80.

VERU Dernières nouvelles

Plus de nouvelles

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

MIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...

31 Décembre 2024
GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness

17 Décembre 2024
Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

16 Décembre 2024
Edgar (US Regulatory)

Form POS AM - Post-Effective amendments for registration statement

12 Décembre 2024
Edgar (US Regulatory)

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

MIAMI, FL, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...

26 Novembre 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

12 Novembre 2024
Edgar (US Regulatory)

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

MIAMI, FL, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...

05 Novembre 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

04 Novembre 2024
Edgar (US Regulatory)

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

MIAMI, FL, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...

21 Octobre 2024
GlobeNewswire Inc.

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

MIAMI, FL, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...

16 Octobre 2024
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.2534.24657534250.730.990.703422712750.78490029CS
40.34554.33070866140.6350.990.60421050260.71464864CS
120.10111.49032992040.8790.990.57513240120.70938048CS
26-0.1299-11.70375709521.10991.130.5759271200.76719156CS
520.55127.9069767440.431.920.3616038960.92152324CS
156-4.82-83.10344827595.824.550.3644544519.88986835CS
260-3.12-76.09756097564.124.560.3634100929.79016557CS

VERU - Frequently Asked Questions (FAQ)

What is the current Veru share price?
The current share price of Veru is US$ 0,98
How many Veru shares are in issue?
Veru has 146 383 920 shares in issue
What is the market cap of Veru?
The market capitalisation of Veru is USD 123,5M
What is the 1 year trading range for Veru share price?
Veru has traded in the range of US$ 0,36 to US$ 1,92 during the past year
What is the PE ratio of Veru?
The price to earnings ratio of Veru is -3,8
What is the cash to sales ratio of Veru?
The cash to sales ratio of Veru is 8,49
What is the reporting currency for Veru?
Veru reports financial results in USD
What is the latest annual turnover for Veru?
The latest annual turnover of Veru is USD 16,89M
What is the latest annual profit for Veru?
The latest annual profit of Veru is USD -37,8M
What is the registered address of Veru?
The registered address for Veru is 301 S. BEDFORD ST, SUITE 1, MADISON, WISCONSIN, 53703
Which industry sector does Veru operate in?
Veru operates in the FABRICATED RUBBER PDS, NEC sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
BTCTBTC Digital Ltd
US$ 8,2697
(73,73%)
61,45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8,80
(62,36%)
18,63M
CRKNCrown Electrokinetics Corporation
US$ 0,1235
(54,96%)
764,86M
NUKKNukkleus Inc
US$ 29,97
(45,98%)
19,09M
GSITGSI Technology
US$ 3,97
(44,36%)
87,7M
DOGZDogness International Corporation
US$ 18,23
(-58,77%)
740,45k
ORKTOrangeKloud Technology Inc
US$ 3,02
(-24,88%)
21,08M
PMAXPowell Max Ltd
US$ 0,6364
(-23,31%)
4,17M
LGCBLinkage Global Inc
US$ 0,2876
(-22,27%)
890,66k
YYAIConnexa Sports Technologies Inc
US$ 0,8299
(-20,20%)
602,48k
CRKNCrown Electrokinetics Corporation
US$ 0,1235
(54,96%)
764,86M
GCTKGlucoTrack Inc
US$ 0,0852
(15,45%)
465,22M
RIMEAlgorhythm Holdings Inc
US$ 0,0406
(-4,02%)
387,23M
TGLTreasure Global Inc
US$ 0,2459
(14,75%)
267,1M
NVDANVIDIA Corporation
US$ 137,71
(3,10%)
201,4M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
VERU
Veru
ASE
ELPEE
Hellenic Petroleum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés